Effort to focus on life sciences, other knowledge-based industries see more
In preparation for an anticipated economic rebound once the effects of the COVID-19 health crisis subside, the Richland County Economic Development Office (RCEDO) has teamed with a group of regional partners to develop an economic development action plan for promoting the growth of knowledge-based industries within the region.
RCEDO is also collaborating on the plan’s marketing components with those partners, which include Lexington County, the City of Columbia, the University of South Carolina, Midlands Technical College, the S.C. Research Authority (SCRA) and the Central SC Alliance.
The initiative focuses on five knowledge-based industry segments: information technology/data analytics, financial services, aerospace, medical devices and the biosciences. It is designed to build on existing assets in the region and capitalize on the growing base of research, innovation and industry partnerships at the University of South Carolina.
“I am exceptionally proud that the entire economic development community in our region has united to ensure that we can more effectively compete to expand the number of knowledge-based jobs,” said Paul Livingston, chair of Richland County Council. “This initiative will have a substantial economic impact on the whole region.”
The plan also contains a robust marketing component, and RCEDO will collaborate with its regional alliances to implement key strategies. The development office will coordinate with partners to position and promote the Columbia region as a technology and innovation hub.
“South Carolina is among the most successful states in the nation in building its manufacturing base, but the state has not been as successful in generating jobs in knowledge-based industries,” said Garry Powers, who is overseeing the project for the County as a member of the Economic Development staff.
“The Columbia metro area has the highest concentration of software-related employment in the state, and bioscience-related companies are expanding rapidly in the region,” said Jeff Ruble, RCEDO director. “Therefore, once we adapt our economic development and workforce programs so that we have an improved capacity to support companies in these targeted industries, the Midlands region is well positioned to substantially increase employment, both within our existing firms and within the new firms that we will attract to the region.”
As part of this initiative, Deloitte Consulting has analyzed the region’s capacity to grow employment in the targeted industry segments. Using this information, the company developed a detailed action plan that mitigates competitive weaknesses and builds on the region’s strengths.
To assess the Midlands’ competitive position, Deloitte measured the region’s capacity to support industry expansion compared with more than two dozen other metro areas that are hotbeds of knowledge industry growth.
Further, the initiative identifies opportunities to improve the region’s competitive position in a variety of areas, including:
- Enhancing education/training programs based on an analysis of industry needs
- Expanding programs that build the talent pipeline
- Ensuring there is sufficient infrastructure (e.g., wet labs, broadband, real estate) to support the targeted industries
- Restructuring state/local education and training incentives and other state/local incentives to ensure they are competitive nationally
The SCRA is an active partner in the project because of its mandate to promote the growth of the state’s innovation economy by accelerating technology-enabled growth in research, academia, entrepreneurship and industry. Deloitte’s action plan includes provisions for growing existing small firms and attracting new, innovative small firms within the targeted industry segments. The plan will especially focus on firms capable of building university partnerships.
The project is expected to provide substantial economic development benefits statewide, and the region has established strong, project-related working relationships with several entities. These include the S.C. Department of Commerce, the State Board for Technical and Comprehensive Education, the S.C. Council on Competitiveness and SCBIO, a statewide, not-for-profit, public–private economic development organization that actively promotes, builds, supports, expands and convenes the state’s life sciences industry.
Lindsay Cobbs named to head KPIC at USC see more
The Kennedy Pharmacy Innovation Center (KPIC) announced that James Lindsay Cobbs has been named chair for the center.
In his role, Cobbs will focus on creating a regulatory affairs program for students in the College of Pharmacy, including classroom, cocurricular, experiential, and post-graduate opportunities, as well as supporting Nephron Pharmaceuticals in regulatory affairs.
“My priorities will hone in on developing experiential training opportunities that will enable our students to build skills for both traditional and nontraditional pharmacy roles, developing key partnerships that can support training for our students and to identify ways that will make the College of Pharmacy stand light years apart from other colleges across the country,” says Cobbs.
Cobbs brings a wide array of career experiences to KPIC, ranging from clinical pharmacy to global policy development in the pharmaceutical industry. After graduating from the UofSC College of Pharmacy in 1992, he launched his career as a staff pharmacist at Johns Hopkins Medical Center. After four years, he entered public service as a regulatory affairs professional at the U.S. Food and Drug Administration (FDA) where he served as regulatory project manager, special assistant and lead project manager in the Office of Compliance and later as associate director for regulatory affairs (ADRA) in the Office of Translational Sciences.
Cobbs then transitioned to the corporate sector at Janssen Pharmaceuticals, a division of Johnson & Johnson as a policy lead in the Americas, Global Regulatory and Policy Intelligence Department. Cobbs later became the head of US Policy, Global Regulatory Policy and Intelligence for UCB (Union Chimique Belge translated as Union Chemical of Belgium), a multinational biopharmaceutical company headquartered in Brussels, Belgium.
Cobbs says his various roles have led him to this next challenge. “My experience as a pharmacist at a major teaching institution, working as a public health servant, co-leading drug review teams for novel drug products, and regulatory policy and intelligence in the pharmaceutical industry have prepared me for this unique role,” he says.
Patti Fabel, Pharm.D. and executive director of KPIC is looking forward to joining efforts with Cobbs. “Our faculty, staff, and students can learn a great deal from him due to his background, experience and skill set,” Fabel says. “He will broaden the scope of what KPIC can offer our students and alumni by developing a regulatory affairs program. I’m excited to see the impact he has on the center and college.”
Dean Stephen J. Cutler says Cobbs is an exceedingly accomplished expert in pharmaceutical regulatory affairs. “His addition to our faculty will bring added depth and breadth to our educational program as we launch our college’s latest initiative, the Regulatory Affairs Academic Program,” Cutler adds. “This academic program will offer regulatory education to our pharmacy students, provide postgraduate education for residents and fellows, and give another educational track to our graduate program. Our partnership with Nephron Pharmaceuticals will afford us a working laboratory for the development of future pharmacists and scientists serving in regulatory affairs. We are thrilled that Lindsay Cobbs will shepherd this initiative for the College of Pharmacy.”
Cobbs will begin his role on July 1, 2020.
SCBIO Newsletter - Mid-June 2020: SC Leaders Weigh In June 23 on Securing State's Future Post-COVID & More!Important SC life sciences news and updates from SCBIO see more
Don't miss this latest issue of SCBIO's semi-monthly newsletter, chock full of great articles, events, updates, connections, resources and more.
SC's Post-COVID Future to be discussed June 23 in free webinar see more
Four leaders from the Palmetto State will be joined by a national expert on Infectious Disease June 23 at 10 a.m. for a free webinar discussion on leadership strategies to help South Carolina weather the challenges of COVID-19 and rebound rapidly from the health, social and economic impacts of the pandemic.
Entitled “Bold Leadership in the Eye of the Storm: Insights & Strategies to Secure Our Future", the program will feature U.S. Senator Lindsey Graham; University of South Carolina President Robert Caslen; Lou Kennedy, CEO of Nephron Pharmaceuticals; and Dr. Phyllis Arthur, VP Infectious Diseases and Diagnostics Policy, BIO. The group discussion will be moderated by Sam Konduros, CEO of SCBIO, the state’s life sciences economic development organization.
The group will discuss such topics as:
- How major universities, colleges and school systems will strive to safely reopen to welcome back students in the Fall, while also encouraging participation in related educational and social activities that are core to the educational experience
- National/global feedback on how the life sciences industry has fared to date in the ongoing battle against COVID-19 and other infectious diseases, and the likelihood and timing for major advances in testing, treatment and vaccines becoming available across the country
- Industry’s perspective on the approach taken to accelerate the reopening of South Carolina’s economy, and what must be done to ensure safety for citizens while battling against the troublesome economic downturn the pandemic has created
- The strategic importance of developing policy around the re-shoring production of essential healthcare equipment, pharmaceuticals and ingredients, personal protective equipment and other medical products and devices back to the US and South Carolina from abroad.
Participation in the webinar is free to all interested parties. Those wishing to participate can register while space remains at https://www.scbio.org/events/lessons-learned-by-industry-government-higher-education-from-the-covid-crisis.
The 60-minute program will provide attendees with a real-time review of the pandemic’s impact in South Carolina to date, implications for returning to normalcy in the upcoming months, and insights and strategies to secure and enhance the state’s future. The panelists will also address a realistic path forward as South Carolina begins the move to return to normalcy while still navigating a virus with no clear endpoint.
“Our goal is to bring the diverse viewpoints of top leaders in government, industry, education and the life sciences industry together in one forum to assess where we are, and how we can make a difference for our citizens in recovering from COVID-19’s impact in the weeks to come,” said SCBIO CEO Sam Konduros.
“The panelists will also share their insights on important lessons learned, strategies for the future, and ways for all South Carolinians to come together to solve health, social and economic challenges and improve quality of life for our citizens,” he added.
SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state. The industry has an $11.4 billion annual economic impact in the Palmetto State, with more than 600 firms directly involved and 43,000 professionals employed directly or indirectly in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products. The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries. As the official state affiliate of BIO, PhRMA and AdvaMed, SCBIO members include hundreds of academic institutions, biotech companies, medtech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups.
For additional information on SCBIO, visit www.SCBIO.org.
USC among best in world for patents see more
Courtesy of Columbia Regional Business Report
The University of South Carolina ranked among the top 100 universities worldwide for number of U.S. utility patents received by faculty members in 2019, marking the eighth consecutive year the university made the top 100.
USC ranked 90th in the world in 2019 with faculty named as the lead on 31 patents, according to a news release from the university.
The annual list (.pdf) has been published by the National Academy of Inventors and the Intellectual Property Owners Association since 2013. Rankings are based on the number of utility patents granted by the U.S. Patent and Trademark Office that list a university as the first assignee.
“Our faculty’s ability to create new technologies and innovate year after year is one of our great strengths as a university,” said Bill Kirkland, executive director of USC’s Office for Innovation, Partnership and Economic Engagement. “Their continued contributions to scientific discovery ultimately improve the quality of life not just our state, but all over the world.”
USC is the only S.C. institution to make the list.
The Regents of the University of California, the governing board of the University of California, topped the rankings with 631 patents.
Nephron steps up to support USC's planned reopening with donations of sanitizer see more
Nephron Pharmaceuticals Corp. is donating more than 100,000 bottles of company-manufactured hand sanitizer to the University of South Carolina as part of the West Columbia-based company's ongoing efforts to help fight COVID-19.
The first 5,000 bottles arrived on campus today, hand-delivered by Nephron president and CEO Lou Kennedy and Nephron's new van bearing its clinical lab logo to a group of student leaders on the university’s Horseshoe.
“No matter how tall the challenge is, Gamecocks step up,” Kennedy, a 1984 USC graduate, said in a news release. “Our company is proud to do our part to help the university make sure it is ready to welcome students, staff and faculty back to campus.”
USC, which closed its campuses in March in response to the COVID-19 pandemic, is resuming in-person instruction in mid-August.
“We’re grateful to Lou and Bill Kennedy and the entire team at Nephron Pharmaceuticals for this generous gift,” Bob Caslen, USC president, said. “This donation helps support the safe return of our students and employees to campus and exemplifies what the Gamecock spirit is all about: making our communities better through selfless service and caring for others.”
The bottles bear a private label requested by the university, Kennedy said.
Nephron develops and produces generic respiratory medication, including inhalation solutions and suspension products that can be used to treat severe respiratory symptoms associated with COVID-19.
In March, Nephron began making its own hand sanitizer, and previously donated 50 liters to the William Jennings Bryan Dorn Veteran Affairs Medical Center. The company added a production line in April be used in the manufacturing of bronchodilator albuterol as demand for its products soars during the pandemic.
Last month, the company announced an expansion of its COVID-19 testing capabilities through a partnership with medical technology company One Medical. Kennedy told the Columbia Regional Business Report today that Nephron’s on-site clinical lab began testing company employees last week and plans to process samples collected during a drive-thru testing clinic June 19 and 20 at Benedict College’s football stadium.
“We are trying to be a good partner with DHEC, a good partner with the local hospitals, and see how we can take some of the stress off of their labs for testing,” said Kennedy, who said Nephron has also developed, in partnership with Lexington Medical Center, a transport medium for nasal swabs used in the testing process.
Nephron has hired its own nurse practitioner and installed a chief medical officer, Kennedy said. She said the department-by-department testing of employees will continue through this week.
“The more we test, we’re going to find people that are asymptomatic, but it’s important for us to get this contact tracing thing figured out, get a baseline, get people home and get them well,” she said.
Universities are the largest job creators in two thirds of America's largest cities see more
Human psychology primes us to see marquee projects like Amazon's HQ2 as the pinnacle of economic development. Big-name corporate partners capture people’s imagination, with promises of new jobs and state-of-the-art campuses that will revitalize long-stagnant neighborhoods, practically overnight. However, perspective can be easily lost in all this excitement. For every region like the Washington D.C. metro area that secures an HQ2-like award, there are hundreds of other places that thrive off lower-profile, but no less important, economic anchors.
Universities, for example, are the largest job creators in 66 of the 100 largest U.S. cities. Part of the reason that these figures do not regularly make headlines is that they have been regarded as gospel for generations of economic developers.
Read how, through the thought leadership of University of South Carolina’s (UofSC) former president, Dr. Harris Pastides, USC proactively confronted this challenge. Click for full article from Route Fifty.
USC sets record for research funding see more
University of South Carolina faculty have again broken their previous record-high external funding by garnering $278.6 million in research and sponsored awards in fiscal year 2019 (July 1, 2018 through June 30, 2019). FY2019 was the fifth consecutive year of record-breaking funding totals, beating the previous record of $258.1 million, set in fiscal year 2018, by 8 percent.
UofSC Vice President for Research Prakash Nagarkatti said, “Sustained growth of this magnitude does not happen by accident. By making strategic investments in our exceptional scholars and our infrastructure, the University of South Carolina is building a research community characterized by innovation and excellence that has made and will continue to make an enormous positive impact on our state, nation and world. I am so honored to work with such outstanding faculty, students and staff, who continue to raise the bar year after year.”
Vice President Nagarkatti credits strategic internal investments in research and infrastructure with helping to generate the growth that has increased research and sponsored awards totals for each of the past five years. The Advanced Support for Innovative Research Excellence, or ASPIRE program, provides an example of how internal programs that fund meritorious research and multi-user infrastructure generate strong returns on investment. Since its inception in 2012, ASPIRE has provided $16.1 million to fund 597 faculty and postdoctoral scholar research projects in subject areas from art to mathematics and from medicine to library science. Past ASPIRE recipients have garnered more than $171.2 million in subsequent extramural funding, including $71.8 million in funding that was directly attributable to groundwork laid with an ASPIRE award. This represents more than a four-fold direct return on investment.
5-year Phase II COBRE grant will result in more funding to support research conducted at USC see more
The National Institutes of Health (NIH) has awarded the University of South Carolina a five-year grant totaling more than $11.2 million to support the COBRE Center for Targeted Therapeutics based at the College of Pharmacy. This is Phase II of the COBRE grant, and follows the five-year Phase I portion of the research grant, which concluded this year.
The COBRE Center for Targeted Therapeutics (CTT) is directed by SmartState endowed chair and drug discovery and biomedical sciences professor Dr. Igor Roninson, an internationally-recognized researcher in cancer therapeutics.
“Dr. Roninson is an exceedingly accomplished scientist and has been successful in navigating the transition of this Center from the Phase I stage to the Phase II, which is not an easy task. Less than one-half of the Phase I COBREs are successfully converted into a Phase II program,” said Dr. Stephen J. Cutler, Dean of the College of Pharmacy. “Under the Phase I Center, Dr. Roninson has directed the advancement of young faculty members into independently funded scientists, supported the growth of a critical mass of investigators focused on the design and discovery of new therapeutic agents, and enhanced the development of new research cores at the University of South Carolina. Under the Phase II Center grant from NIH, Dr. Roninson should be able to strengthen the Center for Targeted Therapeutics at the UofSC.”
Dr. Roninson was awarded the five-year Phase II COBRE grant of $2,235,000 annually from the National Institutes of Health to support the CTT. This Center was created to attract and foster the professional development of talented junior scientists dedicated to research in the treatment of debilitating diseases and to develop the infrastructure for targeted therapeutic studies.
“Dr. Roninson’s Phase I COBRE-CTT established a cadre of highly talented and successful junior faculty in the College of Pharmacy, College of Arts and Sciences, and the School of Medicine, whose research efforts focused on the discovery of new drug targets,” said Dr. Kim Creek, Associate Dean of Research at the College of Pharmacy. “The impact of the COBRE-CTT on research productivity at UofSC is substantial and far reaching. The Phase II award will provide funding for the COBRE-CTT for an additional five years and will support the hiring of additional junior faculty in the area of targeted therapeutics and allow for overall growth of this thriving Center.”
The Center for Targeted Therapeutics includes three resource cores, including the Functional Genomics Core, the Drug Design and Synthesis Core and the Microscopy and Flow Cytometry Core. A core director is assigned to each of the research cores. These experts provide scientific advice in project development, along with technological support.
For more information on the College of Pharmacy’s COBRE Center for Targeted Therapeutics, visit: https://tinyurl.com/yyy72s6c
USC Upstate invited to be a member of the SC IDeA Networks of Biomedical Research Excellence see more
SPARTANBURG — The University of South Carolina Upstate has been invited to be a member of the South Carolina IDeA Networks of Biomedical Research Excellence (SC INBRE) as a Primarily Undergraduate Institution. As part of the application process, they detailed plans for an eight-week summer research program to support five to six faculty researchers and up to 12 student researchers yearly. If South Carolina is renewed as an IDeA state in 2020, Upstate will receive $500,000 to fund the summer program that they call ER(Up)T (Engaged Research and Training at Upstate) from 2020-2025.
“Investment in the ER(Up)T program will allow USC Upstate to mentor and engage the next generation of biomedical scientists and create a pipeline to increase the number of skilled biomedical professionals in South Carolina,” said Dr. Jeannie Chapman, interim dean of the College of Science and Technology at USC Upstate. “While there is biomedical research being conducted at USC Upstate, the ER(Up)T program will increase our ability to attract and retain more undergraduate students in our laboratories and further enhance the research culture at our institution, particularly amongst underrepresented minorities.”
“This new funding will create a summer research program that offers transformative, high-impact learning experiences for students who wish to pursue a career in biomedical research,” said Dr. Joshua Ruppel, associate professor of chemistry, co-author of the SC INBRE proposal, and ER(Up)T program director. “Over the course of eight weeks, students will conduct research in the laboratory with a faculty mentor and attend a number of research-related activities, including lab meetings about ongoing research, scientific ethics seminars, and graduate school information sessions. The students will be immersed in the culture of basic science research, and they will be provided opportunities that enhance their ability to achieve their career goals.”
According to Chapman, “USC Upstate is uniquely suited to enhance the pipeline of students attending graduate and professional schools in South Carolina. Our student body is primarily composed of S.C. residents (94% of all enrolled students), many of whom choose to stay in South Carolina upon completing their degrees. The research and programming that students will experience through ER(Up)T will increase students’ knowledge of careers in the biomedical sciences, groom them for graduate and professional school, and will ultimately enhance South Carolina’s biomedical industries by way of a better-educated and more scientifically-minded workforce.”
Both Chapman and Ruppel have a clear vision of how creating a summer research program will enhance the biomedical research currently underway at USC Upstate.
“USC Upstate has a vibrant biomedical research program, spearheaded by five faculty in the Division of Natural Sciences and Engineering,” Chapman said. “During the past five years, their combined research efforts have resulted in 20 peer-reviewed publications that have included multiple undergraduate co-authors, 46 scholarly presentations, and $652,000 of internal and external funding. While their individual efforts and achievements are impressive, this funding support from SC INBRE allows us to create a cohesive undergraduate research program.”
Current biomedical research at USC Upstate includes:
• Dr. Joshua Ruppel, associate professor of chemistry, received a National Institutes of Health (NIH) Academic Research Enhancement Award (AREA) Program (R15) in collaboration with Dr. Nicole Snyder of Davidson College to support meritorious research, expose students to research, and strengthen the research environment of the institution. His research is used to create and study the interaction of a class of new compounds with a protein associated with certain types of cancer.
• Dr. Bradley Baumgarner, assistant professor of biology, investigates the effect of various xenobiotics on skeletal and cardiac muscle metabolism, growth, and differentiation. In the past five years, his work has been focused on defining the mechanisms by which caffeine promotes macroautophagy and its role in regulating caffeine-dependent protein turnover (protein synthesis/protein degradation) in mammalian skeletal muscle cells.
• Dr. Ginny Webb, assistant professor of microbiology, investigates virulence factors of Cryptococcus neoformans, a facultative intracellular pathogen responsible for the most common cause of fungal meningitis worldwide. She also investigates the transmission of hospital acquired infections, which are a growing public health concern, accounting for 1.7 million infections each year in inpatient or outpatient medical facilities. The research aims to study the mechanisms of transmission of hospital-acquired infections with specific examination of pediatrician outpatient facilities to determine what touch surfaces may harbor pathogenic organisms and therefore potentially serve as a reservoir for harmful microbes.
• Dr. Anselm Omoike, assistant professor of chemistry, investigates the unique magnetic, large surface area, and nontoxic properties of iron oxide nanoparticles (magnetite) in synthesizing materials for drug delivery and biochemical separations. One aim is to coat magnetic iron oxide nanoparticles with lysine, producing free surface active amino groups for the delivery of curcumin, a drug with well-established wide ranging chemotherapeutic activities. His other project involves removing allergenic proteins from food products to develop fast and recyclable multilayer magnetic nanoparticles for the removal of major allergens from peanuts and peanut products. This work may contribute to knowledge of the conditions for efficient removal of allergenic proteins from a food system and help produce hypoallergenic peanut products.
• Dr. Kimberly Shorter, assistant professor of biology, investigates the potential negative consequences of excess folic acid consumption and its potential correlation with increases in autism rates. Her lab currently uses a human neuronal cell line as a model for testing the effects of excess folic acid (at a 2x dose) on epigenetic changes (DNA methylation/hydroxymethylation and histone modifications), gene expression changes, and neuromorphological changes (dendritic spines and vesicle trafficking).
SC INBRE is a five-year, $18.2 million renewable grant funded by the National Institutes of Health (NIH) National Institute of General Medical Sciences (NIGMS). Grant funds are administered through the University of South Carolina and go to financially supporting biomedical research throughout the State of South Carolina at SC INBRE’s network institutions and outreach institutions.
“We are very pleased to introduce some new faces in the renewal and are excited to see USC Upstate as one of those new faces,” said Cyndy Buckhaults, communications manager with the SC INBRE Program. “USC Upstate has a very active science research component and will be a great fit with the network.”
The Institutional Development Award (IDeA) program broadens the geographic distribution of NIH funding for biomedical research. The program fosters health-related research and enhances the competitiveness of investigators at institutions located in states that historically have had low levels of NIH funding by supporting basic, clinical, and translational research; faculty development; and infrastructure improvements.
For more information, contact Dr. Jeannie Chapman at 864-503-5768.
About USC Upstate
The University of South Carolina Upstate is a regional comprehensive university offering more than 40 undergraduate and graduate programs in the liberal arts and sciences, business administration, nursing, and education. Located along the I-85 corridor in Spartanburg between Greenville and Charlotte, USC Upstate is ranked by U.S. News & World Report at #2 among Top Public Schools. It serves as a major talent producer for the region, with more than 6,000 students, approximately 1,300 new graduates a year, and nearly 30,000 alumni, many of whom live and work in the state. The USC Upstate Spartans compete in 17 NCAA Division 1 sports as a member of the Big South Conference. For more information, visit www.uscupstate.edu.
Pastides to Chair SC Institute of Medicine & Public Health Board see more
The South Carolina Institute of Medicine & Public Health (IMPH) is pleased to announce new executive officers and members of the Board of Directors. Dr. Harris Pastides has been named Chair and Mr. Joel A. Smith III Vice-Chair. Dr. Pastides is President of the University of South Carolina. Mr. Joel Smith is Dean Emeritus, University of South Carolina Moore School of Business and President (retired) of Bank of America East and will be serving a second term in this role. Ms. Pamela Lackey, President (retired), AT&T South Carolina, is the immediate past Chair.
Dr. Pastides shared, “I am honored to serve as Chair of the Board of Directors for the South Carolina Institute of Medicine & Public Health. South Carolina continues to face persistent and emerging health challenges while the health care and public health systems are adapting to new technologies and payment models. IMPH is uniquely situated to share nonpartisan, evidence-based policy solutions, and I look forward to advancing these matters of importance for all South Carolinians.”
Joining the board for the first time for the 2019-2021 term is Ms. Lou Kennedy, President, Chief Executive Officer and Owner, Nephron Pharmaceuticals Corporation. Ms. Kennedy joined Nephron Pharmaceuticals in 2001 and accepted the position of President and Chief Executive Officer in September 2007. She is currently the new chairman of the South Carolina Chamber of Commerce. She is also involved in a variety of other business and civic boards, including but not limited to, the National Bank of South Carolina Board, USC Athletic Department Board, Columbia College Board of Trustees and the South Carolina Manufacturers Alliance.
Dr. David Cole, President, Medical University of South Carolina; Mr. Joel A. Smith III, Dean Emeritus, University of South Carolina Moore School of Business and President (retired) of Bank of America East; and Mr. Richard Wilkerson, Chairman and President (retired), Michelin North America were all elected for renewed terms to serve 2019-2021.
“I have the privilege of working with an incredible board dedicated to improving health and health care in South Carolina, said Executive Director Kester Freeman. “Ms. Lackey’s vision and leadership has steadily guided the IMPH Board of Directors for the past two years, and I am thankful she will continue her term of service on our board through 2020. Mr. Smith’s re-election as Vice-Chair provides additional continuity of leadership on the executive committee as Dr. Pastides becomes Chair. I am thrilled Dr. Pastides has agreed to provide his leadership and vision as we continue to grow the Institute.”
During the past year, IMPH has undergone an intensive strategic planning process and assessment of operational roles and functions. As a result, new organizational roles have been established to better meet the needs of the Institute. Co-directors Ms. Maya Pack and Dr. Megan Weis will start their new roles effective January 1, 2019.
Ms. Maya Pack will serve as Associate Executive Director. She will continue to lead business and financial management of the Institute, and will now manage all programs and contracts including SCale Down, Behavioral Health and Long-Term Care, the Health Policy Fellows Program and other legislative services.
Dr. Megan Weis will serve as Senior Director of Strategic Engagement to build and expand the Institute’s communications, impact evaluation and development work, as well as continuing to foster relationships in-state and nationally.
With the support of the Board of Directors and the continued executive leadership of Mr. Freeman, these updates will support IMPH’s vision to be the leading and trusted nonpartisan resource for research-based information on South Carolina’s most critical public health issues.
IMPH Board of Directors
- Dr. Harris Pastides, (chair), President, University of South Carolina
- Mr. Joel A. Smith III, (vice-chair), Dean Emeritus, USC Moore School of Business; President (retired), Bank of America East
- The Honorable Terry Alexander, Member, South Carolina House of Representatives
- Mr. William Barnet, CEO, Barnet Development
- Dr. David J. Cole, President, Medical University of South Carolina
- The Honorable Ronnie Cromer, Member, South Carolina Senate
- The Honorable Jim Hodges, President and CEO, McGuireWoods Consulting, LLC; Former Governor, State of South Carolina
- Dr. Chanita Hughes-Halbert, Professor, Medical University of South Carolina
- Ms. Lou Kennedy, President, Chief Executive Officer and Owner, Nephron Pharmaceuticals Corporation
- Ms. Pamela Lackey, President (retired), AT&T South Carolina
- Mr. Ed Sellers, Chairman, Board of Directors, BlueCross BlueShield of South Carolina
- The Honorable Inez M. Tenenbaum, Of Counsel, Wyche P.A.; Former Chairman, U.S. Consumer Product
- Safety Commission; Former Superintendent of Education, State of South Carolina
- Dr. Windsor Westbrook Sherrill, Associate Vice President for Health Research, Clemson University; Chief Science Officer, Greenville Health System
- Mr. Richard Wilkerson, Chairman and President (retired), Michelin North America
- Dr. Gerald Wilson, Surgeon (retired), Midlands Surgical Associates
Chad Hardaway discusses The Office of Economic Engagement at the University of South Carolina and its newest programsChad Hardaway of USC discusses new programs in this interview. see more
The Office of Economic Engagement (OEE) was formed in 2013 at the University of South Carolina to better connect businesses with the resources of a top-tier research institution.
The OEE offers businesses one point of contact at the university. Four critical functions are now all housed under one roof: 1) technology commercialization, 2) the USC/Columbia Technology Incubator, 3) the Innovista Research campus, and 4) the Corporate Solutions Group.
Under this organizational structure, the Office of Economic Engagement builds academic and industry partnerships, facilitates the commercialization of research, connects new and existing businesses with university talent and resources, and fosters entrepreneurship and small business development.
This year, the University of South Carolina is starting a new graduate program, the MS in Technology Innovation and Entrepreneurial Engineering. It is the only graduate program in the State of South Carolina that places a high premium on students with an engineering and science background, blending their technical and business skills in an entrepreneurial way.
Industry subject matter experts to cover what businesses need to know about state industry see more
GREENVILLE, SC – February 14, 2018 – SCBIO will host a half-day program March 14, 2018 -- South Carolina Life Sciences Boot Camp: Essentials of a Growing Industry – to inform and update businesses and professionals from across the state on opportunities, trends and issues facing South Carolina’s fastest-growing industry segment.
To be held at the University of South Carolina’s Arnold School of Public Health in Columbia, the program will run from 8:30 a.m. until 12:30 p.m. and will feature a light breakfast followed by presentations from over half a dozen noted life sciences industry leaders. Confirmed presenters and their topics are:
- Burnie Maybank, Author of the SC Life Sciences Act; Partner, Nexsen Pruet, “Life Sciences industry Economic Development Incentives”
- Stephanie Yarbrough, Partner, Womble Bond Dickinson, “M&A 101 in the Life Sciences Space”
- Kathryn Cole Becker, Principal, Translational Science Solutions, “FDA 101 for Medical Devices”
- Jeff Stover, Partner, Haynsworth Sinkler Boyd, “IP Essentials for Life Sciences”
- John Osborne, Partner, Good Growth Capital, “Introduction to Life Science Innovation & Entrepreneurship”
- Public Policy Hot Topics – Speaker to be announced
Attendance is free to SCBIO members and employees of SCBIO member companies, and available for only $75 to Non-Members. Advance registration is required, and space is limited. To register, visit www.SCBIO.org/Events.
SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state. The industry has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products. The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries.
SCBIO is the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations. SCBIO’s diverse membership is leading research and development of innovative healthcare, agricultural, industrial and environmental biotech and med-tech products that will make a difference across the Palmetto State, and around the world.
For additional information on SCBIO, visit www.SCBIO.org.